Day: September 3, 2020

Patent challenge initiated by Bausch Health CompaniesNESS ZIONA, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that Bausch Health Companies, Inc. (NYSE:BHC) initiated patent infringement action in the U.S. District Court for the District of New Jersey on August 31, 2020 with regards to Perrigo Company plc (“Perrigo”) (NYSE; TASE: PRGO) Abbreviated New Drug Application (“ANDA”) for a generic version of Duobrii® (halobetasol propionate and tazarotene) lotion, for the treatment of plaque psoriasis in adults1.On July 23, 2020, Sol-Gel’s partner Perrigo filed a Notice of first-to-file Paragraph IV Certification asserting...

BARRIE, Ontario, Sept. 03, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced its wholly owned subsidiary MediPharm Labs Inc. will supply premium, formulated cannabis oil to Cann Farm Peru S.A.C., a Lima-based producer and distributor serving Peruvian and other markets in Latin America.This is MediPharm Labs first such agreement in Latin America and the most recent example of the Company’s international growth strategy in action. As part of this strategy, the Company has expanded its addressable medical, wellness and adult-use markets to parts of Asia Pacific, Europe and now Latin America.MediPharm Labs is creating footholds...

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”), Saiba AG(“Saiba”) and DeepVax GmbH (“DeepVax”)Allergy Therapeutics secures virus-like particle (“VLP”) technology platform to broaden vaccine pipeline through licensing agreements with Saiba AG and DeepVax GmbHGroup to investigate potential of VLP technology in oncology and other immune conditions after encouraging proof of concept findingsBuilds on positive ongoing progress in VLP-based peanut allergy candidate vaccineVLP platform to be combined with Allergy Therapeutics’ proprietary adjuvant technology             3 September 2020 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces further investment in virus-like particle (VLP) technology for applications beyond the allergy...

Sensyne Health announces the UK launch of ‘SENSETM’ – a clinical algorithm engine, created in partnership with Microsoft‘SENSETM’ provides a real-time decision support service for clinicians across multiple conditionsNew agreement signed with Chelsea & Westminster Hospital for the first ‘SENSETM’ generated algorithm to be used for COVID-19Oxford, U.K. 03 September 2020: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, today announces it has launched its ‘SENSETM’ system in the UK, developed in partnership with Microsoft and its health cloud technology, as part of an existing strategic partnership between the two organisations.SENSE is a clinical algorithm engine which generates AI algorithms (called SYNEs) for real-time decision support across multiple medical conditions....

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for inherited retinal diseases (IRDs), today announced that Company management will participate in the following upcoming investor conferences:Citi’s 15th Annual BioPharma Virtual ConferenceThursday, September 10, 9:50-10:35 AM EST – Ophthalmology PanelH.C. Wainwright 22nd Annual Global Investment ConferenceTuesday, September 15, 1:30-1:50 PM EST – Fireside ChatCantor Virtual Global Healthcare ConferenceWednesday, September 16, 2:00-2:30 PM EST – Fireside ChatChardan Virtual 4th Annual Genetic Medicines ConferenceTuesday, October 6, 4:15-4:45 PM EST – Fireside ChatPresentation and webcast details can...

TROY, Mich., Sept. 03, 2020 (GLOBE NEWSWIRE) — Altair, (Nasdaq: ALTR), a global technology company providing solutions in product development, high performance computing (HPC), and data analytics, extended its multi-year OEM agreement with Hewlett Packard Enterprise (HPE) to offer the newly enhanced version of Altair® PBS Professional® workload manager and job scheduler across HPE’s industry-leading HPC systems, including HPE Apollo Systems and new line of HPE Cray supercomputers. HPE Pointnext Technology Services, which provides advisory and professional services to design and deploy solutions, will also be used to offer support for Altair’s latest software offering.“Altair and HPE have forged a strong relationship that delivers compelling value for users of the world’s most popular HPC systems,” said Sam Mahalingam, chief technology...

Tuebingen, Germany and Houston, TX, Sept. 03, 2020 (GLOBE NEWSWIRE) —Completed merger with ARYA Life Science Acquisition Corp. and subsequent NASDAQ listing with proceeds from the transaction totaling $253 million (€226 million1) in July 2020.At the closing of the transaction, cash and cash equivalents amounted to $322 million (€288 million1) enabling Immatics to fund operating expenses and capital expenditure requirements for at least 36 months.Expanded ACTengine® clinical programs into Europe with first patient treated with genetically engineered T cell product candidate IMA202 in August 2020; regulatory approval by Paul-Ehrlich-Institute to begin phase I clinical trial with product candidate IMA203 in Germany and to open additional clinical trial sites in the EU.Expanded leadership team with appointment of Cedrik Britten as Chief...

Tübingen, Deutschland und Houston, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) —Abschluss der Fusion mit ARYA Life Science Acquisition Corp. sowie anschließende Börsennotierung an der NASDAQ im Juli 2020 mit einem Erlös von insgesamt 226 Millionen Euro (253 Millionen US-Dollar1).Mit Abschluss der Transaktion verfügte Immatics über liquide Mittel in Höhe von 288 Millionen Euro (322 Millionen US-Dollar1), welche die Kosten für Immatics Investitions- sowie Betriebsaufwand für mindestens 36 Monaten decken werden.Ausbau des klinischen ACTengine®-Studienprogramms in Europa sowie Behandlung des ersten Patienten mit gentechnisch modifiziertem T-Zell-Therapiekandidaten IMA202 im August 2020; Zulassung für Start der klinischen Phase-1-Studie in Deutschland mit dem Produktkandidaten IMA203 durch das Paul-Ehrlich-Institut sowie der Eröffnung weiterer...

New AEM VTEM Plus survey with state of the art equipment and processing to be flown over Alexo-Dundonald. More detailed AEM /Mag surveys planned over 20km2 to confirm possible extents to existing mineralized zones and explore for new targets. Processing products will include B field profiles, B field tau and 3D RDI Models to assist in location of deeper high conductance targets.TORONTO, Sept. 03, 2020 (GLOBE NEWSWIRE) — Class 1 Nickel & Technologies Limited (“Class 1 Nickel” or the “Company”) (CSE: NICO), a Canadian company developing nickel-copper-cobalt sulphide Mineral Resources 45km northeast of Timmins, Ontario, is pleased to announce the appointment of highly regarded Geophysicist Mr. Alan King to the technical management team.Class 1 Nickel is proud to appoint Mr. Alan King to lead our geophysical interpretation and...